Humanigen Inc. (HGEN) Appoints John Hohneker to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
Humanigen Elects John Hohneker, MD, and Kevin Xie, PhD, to Board of Directors
October 20, 2021 7:00 AM EDTBURLINGAME, Calif.--(BUSINESS WIRE)-- Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm, announced today that the Companys Board of Directors (the Board) has elected John Hohneker, MD, and Kevin Xie, PhD, to serve as independent directors of the Company, effective October 19, 2021.
We are excited about the depth and breadth of experience John and Kevin will add to our Board at this important time as we continue our efforts seeking regulatory authorization to commercialize lenzilumab for the treatment of hospitalized COVID-19 patients, while... More
